CD82 (NM_002231) Human Tagged ORF Clone Lentiviral Particle

CAT#: RC200457L2V

Lenti ORF particles, CD82 (mGFP-tagged) - Human CD82 molecule (CD82), transcript variant 1, 200ul, >10^7 TU/mL

Specifications

Product Data

• Type: Human Tagged ORF Clone Lentiviral Particle
• Tag: mGFP
• Symbol: CD82
• Synonyms: 4F9; C33; GR15; IA4; KAI1; R2; SAR2; ST6; TSPAN27
• Mammalian Cell Selection: None
• Vector: pLenti-C-mGFP
• ACCN: NM_002231
• ORF Size: 801 bp
• Sequence Data:
  ORF Nucleotide Sequence

  The ORF insert of this clone is exactly the same as(RC200457).
• OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
• OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.

Reference Data

• RefSeq: NM_002231.3
• RefSeq Size: 1715 bp
• RefSeq ORF: 804 bp
• Locus ID: 3732
• UniProt ID: P27701
• Cytogenetics: 11p11.2
• Domains: transmembrane4
• Protein Families: Druggable Genome, Transmembrane
• Protein Pathways: p53 signaling pathway
• MW: 29.4 kDa
• Gene Summary: This metastasis suppressor gene product is a membrane glycoprotein that is a member of the transmembrane 4 superfamily. Expression of this gene has been shown to be downregulated in tumor progression of human cancers and can be activated by p53 through a consensus binding sequence in the promoter. Its expression and that of p53 are strongly correlated, and the loss of expression of these two proteins is associated with poor survival for prostate cancer patients. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jul 2008]